Adenylate cyclase toxin (ACT) is the key virulence factor of Bordetella pertussis that facilitates its invasion into the mammalian body. 9-[2-(Phosphonomethoxy)ethyl]adenine diphosphate (PMEApp), the active metabolite of the antiviral drug bis(POM)PMEA (adefovir dipivoxil), has been shown to inhibit ACT. The objective of this study was to evaluate six novel amidate prodrugs of PMEA, both phenyloxy phosphonamidates and phosphonodiamidates, for their ability to inhibit ACT activity in the J774A.1 macrophage cell line. The two phenyloxy phosphonamidate prodrugs exhibited greater inhibitory activity (50% inhibitory concentration [IC 50 ] ‫؍‬ 22 and 46 nM) than the phosphonodiamidates (IC 50 ‫؍‬ 84 to 3,960 nM). The inhibitory activity of the prodrugs correlated with their lipophilicity and the degree of their hydrolysis into free PMEA in J774A.1 cells. Although the prodrugs did not inhibit ACT as effectively as bis(POM)PMEA (IC 50 ‫؍‬ 6 nM), they were significantly less cytotoxic. Moreover, they all reduced apoptotic effects of ACT and prevented an ACT-induced elevation of intracellular [Ca 2؉ ]i. The amidate prodrugs were less susceptible to degradation in Caco-2 cells compared to bis(POM)PMEA, while they exerted good transepithelial permeability in this assay. As a consequence, a large amount of intact amidate prodrug is expected to be available to target macrophages in vivo. This feature makes nontoxic amidate prodrugs attractive candidates for further investigation as novel antimicrobial agents.
T
he bacterium Bordetella pertussis is the causative agent of whooping cough occurring mainly in children. The incidence of this disease has been reduced rapidly after the introduction of the vaccination. In developing countries, however, whooping cough remains a significant cause of childhood mortality because of the high cost of vaccine and difficulty in accessing health centers. Moreover, the decline in protection after vaccination and incomplete vaccination of population pose a threat of this disease even to developed countries (1) . For this reason, there is an urgent need of novel approach in the whooping cough therapy.
The adenylate cyclase toxin (ACT) is an important invasive toxin secreted by B. pertussis, which consists of the N-terminal adenylate cyclase (AC) domain and the C-terminal RTX (repeats in toxin) hemolysin domain. Both AC and hemolytic activities are Ca 2ϩ dependent and have been reported to be responsible for the cytotoxic action of ACT, which predominantly occurs through apoptosis (2, 3) . The insertion of RTX moiety into cellular membranes is necessary to mediate the translocation of the AC catalytic domain into the cytosol of host cells (4) . After entry into the cell, the toxin exhibits direct AC activity, which is activated only in the presence of calmodulin. It causes nearly a 1,000-fold increase in the intracellular cyclic AMP (cAMP) levels and elevation of intracellular [Ca 2ϩ ]i level (5-7). 9-[2-(Phosphonomethoxy)ethyl]adenine (PMEA; adefovir, compound 1, Fig. 1 ) is an acyclic nucleoside phosphonate analogue of dAMP with both antiherpesvirus and antiretroviral activities (8) . Adefovir is currently used for the treatment of chronic hepatitis B virus infection (9) . In addition to that, its active metabolite diphosphorylated form PMEA (PMEApp) has been found to inhibit activity of bacterial AC-based toxins, including ACT and edema factor (EF) of Bacillus anthracis (10, 11) . The crystal structures of ACT and EF in complex with calmodulin and PMEApp have been reported (12) . Moreover, PMEA exhibits only marginal inhibition of mammalian ACs and is highly specific for the bacterial toxins (10) . Unfortunately, the absorption of PMEA is limited by low intestinal permeability due to formation of the zwitterionic form at physiological pH (13) . Bis(pivaloyloxymethyl) ester of PMEA [bis(POM)PMEA; adefovir dipivoxil, compound 2, Fig. 1 ] has been designed to mask the phosphonate charges and enhance the lipophilicity of the molecule. This conversion resulted in significantly greater bioavailability of free PMEA (14) .
In vivo, bis(POM)PMEA is first cleaved into PMEA and subsequently phosphorylated by adenylate kinases and then by nucleoside diphosphate kinases into the diphosphate (PMEApp), which is the real active compound (15) . Using bis(POM)PMEA, the bioavailability of PMEA increased from 11% to 25 to 40% based on the administered dose in human (16, 17) . However, the oral absorption of bis(POM)PMEA is limited by rapid degradation of the diester in the gastrointestinal tract and plasma (18) , leading to the nephrotoxicity, which occurs not only at high doses but even in the case of prolonged low-dose (10 mg daily) therapy (19) .
The purpose of the present comparative study was to evaluate several new amidate prodrugs of PMEA as prospective antimicrobial agents acting via inhibition of ACT. Apart from their ability to inhibit B. pertussis ACT-induced intoxication of a macrophage cell line, their cytotoxicity and bioavailability in vitro were taken into account. The effect of the prepared prodrugs on the ACTinduced apoptosis and [Ca 2ϩ ]i elevation was also in the scope of our research.
the experiment, cells were washed with HBSS (135 mM NaCl, 5.9 mM KCl, 1.5 mM CaCl 2 , 1.2 mM MgCl 2 , 25 mM glucose, 10 mM HEPES [pH 7.4]) and preincubated with compounds at concentrations of 0.001 to 30 M for 5 h. After that, cells were exposed to 0.4 g of ACT/ml from B. pertussis for 30 min. Finally, the cAMP content was determined by using the CatchPoint cAMP immunoassay kit (Molecular Devices, Wokingham, United Kingdom). After the addition of lysis buffer (50 l/well) provided by the manufacturer, the cellular content was extracted by shaking the plate at 250 rpm for 10 min. The plate was then centrifuged to remove cell debris, the supernatant was replaced to the assay plate, and immunoassay was accomplished according to the manufacturer's instructions. Fluorescence signal was acquired using an Infinite M1000 plate reader (Tecan Systems, Inc., San Jose, CA).
Cytotoxicity assay. J774A.1 cells were plated onto white 96-well assay plates at a concentration of 5 ϫ 10 4 cells and allowed to attach overnight. Afterward, the cells were washed with HBSS and treated with compounds at the concentration of 0.003 to 30 M for 5 h. Thereafter, cells were treated with ACT (3 g/ml) for additional 5 h. This concentration of ACT, which correspondes to 5-fold of IC 50 (5 h), was sufficient to decrease the viability of cells to 5%. Two negative controls were prepared by incubating cells either in the absence of both the prodrugs and ACT or in the absence of ACT only. The positive control was represented by the cells treated with ACT only. Subsequently, the viability of the cells was assessed using a Cell Titer-Glo luminescent cell viability assay (Promega, Madison, WI) according to the manufacturer's instructions. Measurement of the luminescent signal was done with use of a GENios microplate reader (Tecan Systems).
Transepithelial transport of prodrugs in Caco-2 monolayers. The transport of the tested compounds across the Caco-2 monolayers was studied using the BD BioCoat HTS Caco-2 assay system (BD Biosciences, Bedford, MA) according to the manufacturer's instructions. The cells were seeded into the wells of the transwell insert at a concentration of 2 ϫ 10 5 cells per insert in the seeding basal medium. The cells were left to attach for 48 h, and after that the medium was changed to the enterocyte differentiation medium in which the cells were cultured for next 48 h. Immediately before the transport experiments, the monolayers were washed twice by transport medium (HBSS containing 10 mM HEPES and 25 mM glucose [pH 7.4]) and incubated for 30 min in a CO 2 incubator at 37°C. The integrity of cell monolayers was assessed by monitoring the transepithelial electrical resistance (TEER) using a Millicell ERS apparatus (Millipore, Bedford, MA) and paracellular flux marker, [ 14 C]mannitol (0.15 Ci/insert). Intact cell monolayers displaying a TEER of Ͼ250 ⍀·cm 2 were used in experiments. The transport was initiated by the addition of 1 ml of the transport medium to the acceptor (basolateral) side and 300 l of the transport medium containing 100 M prodrugs to the donor (apical) side. After a 3-h incubation, 50-l aliquots were collected from the donor and acceptor compartment and separated by ion-pairing reversed-phase high-pressure liquid chromatography (HPLC) using a Supelco Discovery C8 HPLC column (150 by 4.6 mm [inner diameter, 5 m]) in a gradient of 50 to 100 mM CH 3 COONH 4 (pH 4.7) and acetonitrile. The flow rate was 0.9 ml/min. The absorption spectra of the eluate were recorded by a photodiode array detector (PDA) at 260 nm. The retention times under the conditions used were as follows: PMEA (compound 1), 6.7 min; bis(POM)PMEA (compound 2), 14.7 min; compound 3, 11.2 min; compound 4, 15.8 min; compound 5, 16.8 min; compound 6, 19.2 min; compound 7, 14.8 min; and compound 8, 15.5 min. The concentrations of PMEA and intact prodrugs in the apical and basolateral samples were calculated from the peak areas by using calibration curves made up from intact prodrug standards. The concentrations of the PMEA-based intermediate metabolites were calculated using the intact prodrug calibration curve. The apparent permeability coefficient (P app ) was calculated from the following equation: P app ϭ (dQ/dt)/C 0 ϫ A, where dQ/dt is the rate of absorption of the drug across the cells, C 0 is the donor compartment concentration at time zero, and A is the area of the monolayer. Empirical P app data were compared to theoretical values obtained by using ADME profiling software (ACD Percepta).
Preparation of crude macrophage extract. J774A.1 cells (2 ϫ 10 9 ) were washed with PBS and suspended in 1.5 ml of 50 mM Tris-HCl buffer (pH 7.4) containing 1 mM dithiothreitol, 5 mM MgCl 2 , and protease inhibitor cocktail. After that, the cells were homogenized four times for 30 s at speed 4.0 m/s in a FastPrep24 instrument. The homogenate was centrifuged at 30,000 ϫ g for 30 min. The supernatant was incubated with streptomycin sulfate for 1 h to remove nucleic acids and centrifuged at 30,000 ϫ g for 30 min. The resulting crude cell extract was desalted on PD-10 columns (GE Healthcare, Piscataway, NJ), divided into aliquots, and stored at Ϫ80°C. The protein content was determined by using a QuantiPro BCA assay kit (Sigma-Aldrich) according to the manufacturer's instructions.
Hydrolysis of prodrugs in macrophage homogenate. A total of 70 l of extract was mixed with 30 l of reaction buffer (1 mM dithiothreitol, 5 mM MgCl 2 , 0.4 mM EDTA, 20 mM Tris-HCl[pH 7.5]) and incubated for 3 h at 37°C in the presence of prodrugs (200 M). Simultaneously, prodrugs were incubated in reaction buffer only serving as negative (no enzyme) controls. Finally, samples were deproteinated by methanol precipitation and analyzed using HPLC that was performed as described above for the transepithelial transport of prodrugs in Caco-2 monolayers. Blank samples were obtained from untreated macrophage homogenate. No interfering peaks were observed, and thus the selectivity was ensured.
Flow cytometry analysis of cell death. The analysis of annexin V binding was carried out with an Alexa Fluor 488-Annexin V/Dead Cell Apoptosis kit (Invitrogen) according to the manufacturer's instructions. Briefly, J774A.1 cells grown to confluence were pretreated with prodrugs at the concentration of 10 M for 2 h, followed by the treatment with ACT (3 g/ml) for an additional 2 h. Two negative controls were prepared by incubating cells either in the absence of both the prodrugs and ACT or in the absence of ACT only. The positive control was represented by the cells treated with ACT only. After the treatment, the cells were collected, washed twice with ice-cold HBSS (containing 10 mM HEPES and 25 mM glucose [pH 7.4]), centrifuged at 250 ϫ g for 5 min, and resuspended in 1ϫ annexin binding buffer at a concentration of 10 6 cells/ml. Then, 5 l of Alexa Fluor 488 Annexin V and 1 l of propidium iodide (PI) (100 g/ml) were added to 100 l of the cell suspension. Cells were gently vortexmixed, and incubated for 15 min at room temperature in the dark. After that, 400 l of 1ϫ annexin binding buffer was added to each tube, and the samples were analyzed by flow cytometry using a FACSAria cell sorter (BD Biosciences, San Jose, CA). For each sample, 10,000 ungated events were acquired. Annexin V ϩ PI Ϫ cells represented an early apoptotic population. Annexin V ϩ PI ϩ cells represented either late apoptotic or secondary necrotic populations. Annexin V Ϫ PI Ϫ cells were considered as viable cells.
Fluorescence measurement of cytosolic [Ca 2؉ ]i. J774A.1 cells were plated onto 96-well assay plates with black bottoms at a concentration of 5 ϫ 10 4 cells and allowed to attach overnight. Prior to the experiment, the cells were washed with recording buffer (140 mM NaCl, 5 mM KCl, 2 mM CaCl 2 , 3 mM MgCl 2 , 10 mM HEPES-Na, 50 mM glucose [pH 7.4]) and preincubated with tested compounds at the concentration of 10 M for 1 to 3 h. To estimate the IC 50 for suppression of ACT-induced [Ca 2ϩ ]i elevation, the prodrugs in a concentration range of 0.003 to 30 M were used. ACT treatment and fluorescent probe (Fura-2 AM) loading and detection were carried out as previously described with minor modifications (23) . Briefly, the cells were loaded with Fura-2 AM (3 M) for 30 min at 25°C in the dark, washed, and allowed to rest in the recording buffer for 30 min. Subsequently, the cells were exposed to ACT at the concentration of 3 g/ml and immediately subjected to continuous fluorescence acquisition at 25°C (excitation alternating between 340 and 380 nm, emitted fluorescence detected at 509 nm) using an Infinite M1000 plate reader (Tecan Systems). The fluorescence signal was recorded every 15 s, and the integration time for each wavelength was 3 s. The measured fluorescence intensity was not corrected for background intensity. The [Ca 2ϩ ]i concentration was calculated by using the the following equation: (24) , where R is the measured 340/380 nm ratio, R min and R max are the ratios in the absence of Ca 2ϩ and when Fura-2 was saturated by Ca 2ϩ , respectively. R min was determined by incubating cells in the recording buffer with 4 mM EGTA instead of 2 mM CaCl 2 , and R max was determined by treating cells with 10 M ionomycin in the recording buffer containing 10 mM Ca 2ϩ . F 380 max and F 380 min are the fluorescence intensities of 380-nm excitations at 0 mM Ca 2ϩ and at Ca 2ϩ saturation, respectively. K d is the dissociation constant (224 nM) describing the interaction of Fura-2 and Ca 2ϩ . Data analysis and statistical procedures. Unless otherwise indicated, the data are presented as means Ϯ the standard deviation (SD) from at least three independent experiments. Statistical evaluation IC 50 and 50% effective concentration (EC 50 ) determinations were performed by using GraphPad Prism version 5.00 for Windows (GraphPad Software). Statistical significance (P Ͻ 0.05) was assessed by using the Student t test.
RESULTS
ACT inhibitory activity of the PMEA prodrugs and their effect on the viability of J774A.1 cells. The inhibition of the enzymatic activity of ACT was assayed in mouse J774A.1 macrophages. PMEA (compound 1; IC 50 ϭ 2.6 M) and its prodrug bis(POM)PMEA (compound 2; IC 50 ϭ 6 nM) were used as reference inhibitors. ACT induced an ϳ10-fold increase in cellular cAMP over the basal level. All of the studied amidate prodrugs 3 to 8 prevented cAMP accumulation more efficiently than PMEA; however, they did not reach the activity of bis(POM)PMEA. Prodrug 7, the most efficient amidate prodrug tested, was ϳ4-fold less potent than bis(POM)PMEA (Table 1) .
Importantly, all studied amidate prodrugs 3 to 8 suppressed the cytotoxic effect induced by ACT (Table 1) . There is a correlation between the enzymatic inhibition activity of prodrugs and their ability to reduce ACT-induced cytotoxicity (Table 1) . Due to the cytotoxicity of bis(POM)PMEA (compound 2) itself, it was not possible to distinguish the ACT-related cytotoxicity and thus estimate EC 50 for this effect. The cytotoxic effect of bis(POM)PMEA was both time and concentration dependent an IC 50 of 2 M (10 h). In contrast, no cytotoxic effect was observed when the cells were treated with amidate prodrugs 3 to 8 themselves for up to 30 M for 10 h.
Flow cytometry analysis of the effect of the PMEA prodrugs on ACT-induced cell death. Since ACT has been found to promote both apoptotic and necrotic cell death (7), we investigated the ability of the prodrugs to prevent these processes. Apoptotic cells were identified and quantified using Annexin V-PI staining with a subsequent flow cytometric analysis. After 2 h of ACT incubation (3 g/ml), the number of apoptotic cells was significantly increased compared to the nonexposed control (Fig. 2) . The pretreatment with the PMEA prodrugs 3 to 8 (10 M) for 2 h resulted in the reduction of both early and late apoptotic cell populations (Fig. 2) , whereas the population of viable cells increased.
There was a correlation between their inhibition activity and ability to reduce ACT-induced apoptosis, with the exception of bis(POM)PMEA (compound 2). This was most likely due to the intrinsic cytotoxicity (apoptotic effects) of bis(POM)PMEA (Fig.  2B ). This observation is in accordance with the results of cell viability assay and confirms the finding that cytotoxic effect of bis(POM)PMEA starts only a few hours after the treatment. 50 Ca 2ϩ values, which were 0.138 Ϯ 0.043 and 0.283 Ϯ 0.075 M for prodrugs 7 and 8, respectively, after 2 h of prodrug pretreatment. These values are in a decent correlation with both IC 50 for the inhibition of ACT enzymatic activity and EC 50 for the prevention of the ACT-induced cytotoxicity determined for these prodrugs (Table 1) .
Transport and metabolic stability of the prodrugs in Caco-2 cell monolayers. A Caco-2 model system was used to assess transmembrane transport of the PMEA prodrugs. The barrier function was confirmed by the permeability of [ 14 C]mannitol, with the average P app reaching 2.03 ϫ 10 Ϫ6 cm/s. Permeation coefficients of all compounds were determined in the apical-to-basolateral direction. Transmembrane transport of free PMEA (compound 1) through the Caco-2 cell monolayer was found to be low (P app ϭ 2.5 ϫ 10 Ϫ8 cm/s). All of the prodrugs showed greater transepithelial permeability (Table 3) . Among them, bis(POM)PMEA (compound 2) and prodrug 7 were the most permeable. The order of the apparent permeability across Caco-2 was as follows: bis(POM)PMEA (compound 2) Ͼ compound 7 Ͼ compound 8 Ͼ compound 6 Ͼ compound 5 Ͼ compound 3 Ͼ compound 4. All of the prodrugs, except for prodrug 3, underwent enzymatic degradation during their passage through the Caco-2 cell monolayers, and their metabolites were detected in both apical and basolateral compartment (Table 3) . Bis(POM)PMEA showed the highest enzymatic instability, followed by prodrugs 4, 7, 8, 6, 5, and 3. Bis(POM)PMEA was metabolized to PMEA and an intermediate product (mono ester) (retention time [R t ] ϭ 10.2 min). Besides PMEA and intact prodrug, PMEA-based intermediate product (R t ϭ 9.6 min) was observed for the amidate prodrugs.
The second PMEA-based intermediate product (R t ϭ 8.6 min) was identified for prodrugs 7 and 8. Although the degree of degradation of bis(POM)PMEA was the same in both the apical and basolateral spaces, a higher degradation rate was observed in the apical space compared to the basolateral space for the other prodrugs (Table 3) . Empirical P app values were found to be significantly lower than those calculated in silico by ADME profiling software (ACD Percepta) ( Table 3 ). The theoretical and experimental values were comparable only in the case of the prodrug 3, which displayed extreme stability during the transcellular transport (Table 3) .
Hydrolysis of the PMEA prodrugs in J774A.1 cell homogenate. As a next step, hydrolysis of all of the studied prodrugs to free PMEA in macrophage homogenate (i.e., the target tissue) was also evaluated. Based on the retention times and spectral properties, the hydrolytic products in macrophage homogenate were identical to those found in Caco-2 cells. However, the degree of hydrolysis was higher than in Caco-2 cells, and prodrug 3 also underwent a partial degradation in macrophage homogenate (Fig. 3) . Hydrolysis of the prodrug 3 led to the appearance of PMEA and intermediate product with the retention time 8.2 min. The ability of the prodrugs to release free PMEA was in the following order: bis(POM)PMEA (compound 2) Ͼ compound 7 Ͼ compound 8 Ͼ compound 6 Ͼ compound 5 Ͼ compound 3 Ͼ compound 4 (Fig. 3) . Although compound 4 was relatively unstable in homogenate, the intermediate product was detected as a major degradation product (Fig. 3) . All of the prodrugs were stable in the reaction buffer at 37°C.
DISCUSSION
Adefovir diphosphate (PMEApp) has been shown to inhibit adenylate cyclase activity of edema factor (EF) and adenylate cyclase toxin (ACT), the key virulence factors of Bacillus anthracis and Bordetella pertussis, respectively (10, 11) . Although the prodrug bis(POM)PMEA (compound 2, Fig. 1 ) represents a well-established and regulatory authorities-approved antiviral agent, which significantly increases PMEA (compound 1) bioavailability, it suffers from several disadvantages. First, it is degraded extensively during the passage through intestinal membranes (18) . The next drawback is its dose-dependent cytotoxicity (19) . Therefore, the search for new prodrugs continues.
Since B. pertussis has been observed to survive inside the macrophages due to the ACT production (5), the murine macrophage cell line J774.A invaded by recombinant ACT was used to search for membrane-permeable inhibitors of ACT. Based on primary screen, the six amidate prodrugs of PMEA (compounds 3 to 8) with IC 50 in the range of 22 nM to 3.9 M were subjected to further investigations, including the prediction and determination of their intestinal permeability, metabolism, and cytotoxicity, as well as the effect on the intracellular [Ca 2ϩ ]i level. Bis(POM) PMEA (IC 50 ϭ 6 nM) and PMEA (IC 50 ϭ 2.6 M) were used as benchmark controls.
For orally administered drugs, the intestinal epithelial membrane forms the first barrier to drug absorption. Caco-2 cell system is widely used as a predictive and screening tool for intestinal absorption of the prodrugs (25) . In vitro studies using Caco-2 system have demonstrated a low permeability coefficient for PMEA due to formation of the zwitterionic form at physiological pH (13) . Expectedly, the transmembrane transport through Caco-2 cell monolayers has been found much higher for PMEA prodrug bis(POM)PMEA than for PMEA itself (8.8% and Ͻ0.1% of total transport, respectively) (26). In our study, all prodrugs tested enhanced PMEA permeability. However, experimentally determined P apps values were found to be significantly lower than those obtained by ADME profiling software (ACD Percepta). The most likely cause of this discrepancy is that these predictions look into the passive transport based on physicochemical parameters, including lipophilicity and ionization, but side processes such as chemical stability, active transport, and metabolism are omitted. Caco-2 cells express variety of apical and basolateral membrane efflux transporters such as P-glycoprotein (apical) or multidrug resistance proteins (MRPs; apical and basolateral). Although the acyclic nucleoside phosphonates appeared to be substrate for MRPs, their prodrugs have been shown to be substrates for apical efflux via P-glycoprotein (27, 28) . Further, bis(POM)PMEA has been shown to spontaneously hydrolyze to the mono(pivaloyloxymethyl) ester of PMEA [mono(POM)PMEA], which is then converted to PMEA by cellular carboxylesterase in Caco-2 cells (26, 29) . In accordance with the previously reported data, we detected the high susceptibility of bis(POM)PMEA to enzymatic degradation. Phosphonodiamidate (bis-amidate) prodrugs have been proved to be hydrolyzed by lysosomal carboxypeptidase cathepsin A (CatA) (30) . Bis-amidates 3 to 6 involved in our study may be expected to be metabolized in the same way as GS-9191 prodrug [bis-amidate prodrug of 9-(2-phosphonylmethoxyethyl)-N6-cyclopropyl-2,6-diaminopurine] with monophenylalaninyl derivative as an intermediate metabolite. CatA has been identified as a main hydrolase involved in the intracellular metabolism of GS-9191 in various cancer cell lines (31) . CatA is highly expressed in macrophages (32) . In the intestinal cells polarity of CatA expression was observed. Although the mucosal (apical) layer expresses CatA moderately, little protein is expressed basolaterally (33) . The differences in the amount of intact prodrug in apical and basolateral space, which we observed for phosphonodiamidates but not for bis(POM)PMEA, could be attributed to this fact. In the case of prodrugs 7 and 8, aside from CatA, another enzyme will take part in their metabolism, carboxylesterase, or phosphodiesterase (34) . Definitely, the mechanism of their hydrolysis is distinct from that of bis-amidates and seems to be responsible for higher degree of their hydrolysis. Therefore, further studies are needed to confirm the involvement of cathepsin A, carboxylesterase, and phosphodiesterase in bis/mono-amidate degradation, as well as to determine the kinetic parameters of degradation using isolated enzyme.
An ideal prodrug should exhibit good stability during the transport across the intestinal membrane, while it has to release the active compound at the target tissue. Since the cleavage of prodrugs is dependent on the cell type and the expression level of the degradation enzymes (35) , the prodrugs in our study were subjected to the action of esterases present in macrophage homogenate. In these cells, the same intermediate products were detected, but the degree of the prodrugs cleavage was higher in macrophages than that in Caco-2 cell line.
To sum up, the data predicted for passive transport obtained by in silico modeling correlate with ACT inhibition activities of prodrugs 3 to 8 only when corrected with the amount of PMEA hydrolyzed from prodrug in macrophage homogenate. However, the activity of prodrug 7 could be comparable to that of bis(POM)PMEA in vivo because of its higher stability in Caco-2 cells. Besides the ability of the prodrugs to inhibit enzymatic activity, we focused on their efficiency to suppress the ACT-related cytotoxicity as well. Both hemolytic (pore-forming) and enzymatic activities has been proved to be involved in the cytotoxic effect of ACT (36) . It should be noted that both of these qualities of ACT largely depend on the origin, preparation, and handling of ACT. Therefore, ACT concentration needs to be adjusted for each assay and laboratory. The PMEA prodrugs 3 to 8 suppressed cytotoxic effect of the ACT in J774A.1 cell line subjected to a concentration of 3 g of this toxin/ml within the interval of 5 h. The flow cytometric analysis confirmed the positive effect of PMEA prodrugs on the viability of cells subjected to the ACT action. These results are in conformity with the finding that the enzymatically inactive but fully hemolytic ACT is a 15-fold less cytotoxic for J774A.1 cells than fully active ACT (36) .
The intrinsic cytotoxity of bis(POM)PMEA has made the estimation of its ACT-protective effect impossible. One of the decomposition products of pivoxil moiety, formaldehyde, has been proved to be responsible for this effect (37) . Although low doses of formaldehyde (10 nM to 10 M) enhanced the viability of cultured cells depending on the cell line used, higher doses enhanced apoptosis via elevation of [Ca 2ϩ ]i (38, 39) . Likewise, bis(POM)PMEA has been previously demonstrated to decrease the viability of macrophages with the IC 50 of 15 M for 24 h of incubation using LDH assay (37) . Our observation on bis(POM)PMEA cytotoxicity showed a decrease of J774.A cell viability with an IC 50 of 2 M for 10 h of incubation using ATP-based assay. This apparent contradiction is clearly due to different conditions of the assay. Regarding the studied amidate prodrugs of PMEA, compounds 3 to 8, no cytotoxic effect was observed for up to the 30 M concentration after 10 h of treatment.
Intracellular calcium alterations have been reported to be involved in processes leading to cell death (40) . Since ACT is able to induce intracellular Ca 2ϩ increase, a potential contribution of this effect to the overall cytotoxicity of ACT has been explored in detail (6, 7, 23) . As a result, two models of Ca 2ϩ entry into the macrophages as a consequence of ACT action have been proposed. According to the first one (6), ACT induces a calcium increase apparently through the opening of cAMP-dependent L-type-like calcium channel. In contrast to that, the second one (7, 23) claims that calcium entry is mediated by neither cAMP nor oligomeric hemolytic ACT pores, but the translocation of the adenylate cyclase domain into the cytosol participates in the formation of a transiently opened calcium path. Neither of these two models proved the correlation between ACT-induced calcium influx and the cytotoxicity of ACT. According to our observation, all of the amidate PMEA prodrugs studied here were able to decrease intracellular [Ca 2ϩ ]i level elevated by the action of ACT. Due to inhibition of adenylate cyclase activity, not only cAMP-dependent L-type-like calcium channels but also the translocation of adenylate cyclase domain can be influenced. The binding of PMEA may prevent adenylate cyclase domain to fold in a correct conformation required for its translocation. As a consequence, the influx of calcium ions could be affected as well.
The ability of amidate prodrugs to reduce ACT-elevated Ca 2ϩ level correlates with both ACT enzymatic inhibitory activity and the prevention of ACT-induced cytotoxicity. However, their enzymatic inhibition potency exceeded their ability to suppress ACT-induced cytotoxicity and Ca 2ϩ influx. A possible explanation is that the inhibition of adenylate cyclase activity by the prodrugs results only in the attenuation of hemolytic activity and calcium influx but not in their complete suppression. Further, our data on the inhibition of the Ca 2ϩ influx support the observation of others (6, 7) that the increase in [Ca 2ϩ ] level is not primarily responsible for the cytotoxicity of ACT. Neverthless, different experimental conditions, including ACT concentration and the mode of its preparation, must be taken into account when comparing the results between various research groups.
In conclusion, we evaluated six amidate prodrugs of PMEA for their ability to inhibit ACT activity. Their inhibitory activity is a function of their lipophilicity and the extent of their hydrolysis to free PMEA in J774A.1 cells. Even though none of the prodrugs 3 to 8 exceeded potency of bis(POM)PMEA for ACT inhibition, all prodrugs tested were more stable to enzymatic degradation in Caco-2 cells. This feature can result in an increase of their bioavailability in vivo. Moreover, in contrast to bis(POM)PMEA, amidates 3 to 8 did not show any cytotoxity under in vitro conditions. In addition, they reduced the cytotoxic effect of ACT more effectively than bis(POM)PMEA. Thus, they merit further investigations.
